X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ACTAVIS (US) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   ACTAVIS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
ACTAVIS
Dec-14
SANOFI INDIA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs4,94519,612-   
Low Rs3,90111,962-   
Sales per share (Unadj.) Rs1,081.83,531.5-  
Earnings per share (Unadj.) Rs141.6-440.7-  
Cash flow per share (Unadj.) Rs185.9324.0-  
Dividends per share (Unadj.) Rs33.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs868.87,659.7-  
Shares outstanding (eoy) m23.03265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.14.5 91.5%   
Avg P/E ratio x31.2-35.8 -87.2%  
P/CF ratio (eoy) x23.848.7 48.8%  
Price / Book Value ratio x5.12.1 247.0%  
Dividend payout %23.30-   
Avg Mkt Cap Rs m101,8624,197,775 2.4%   
No. of employees `0003.221.6 15.0%   
Total wages/salary Rs m3,6850-   
Avg. sales/employee Rs Th7,691.943,473.5 17.7%   
Avg. wages/employee Rs Th1,137.70-   
Avg. net profit/employee Rs Th1,006.5-5,425.0 -18.6%   
INCOME DATA
Net Sales Rs m24,914939,027 2.7%  
Other income Rs m807-2,344 -34.4%   
Total revenues Rs m25,721936,684 2.7%   
Gross profit Rs m5,372120,631 4.5%  
Depreciation Rs m1,022203,334 0.5%   
Interest Rs m1129,619 0.0%   
Profit before tax Rs m5,146-114,665 -4.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,411 0.0%   
Tax Rs m1,886-5,895 -32.0%   
Profit after tax Rs m3,260-117,181 -2.8%  
Gross profit margin %21.612.8 167.8%  
Effective tax rate %36.65.1 712.9%   
Net profit margin %13.1-12.5 -104.9%  
BALANCE SHEET DATA
Current assets Rs m14,432494,747 2.9%   
Current liabilities Rs m6,010360,816 1.7%   
Net working cap to sales %33.814.3 237.0%  
Current ratio x2.41.4 175.1%  
Inventory Days Days6158 105.0%  
Debtors Days Days2866 43.0%  
Net fixed assets Rs m7,991114,665 7.0%   
Share capital Rs m2300-   
"Free" reserves Rs m19,7780-   
Net worth Rs m20,0082,036,716 1.0%   
Long term debt Rs m01,067,279 0.0%   
Total assets Rs m27,7703,732,629 0.7%  
Interest coverage x468.8-2.9 -16,327.4%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.3 356.6%   
Return on assets %11.8-2.3 -502.1%  
Return on equity %16.3-5.8 -283.2%  
Return on capital %25.8-3.0 -856.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m1,0490-   
CASH FLOW
From Operations Rs m4,351161,249 2.7%  
From Investments Rs m-787-386,092 0.2%  
From Financial Activity Rs m-1,884216,928 -0.9%  
Net Cashflow Rs m1,680-7,915 -21.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare SANOFI INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: GLENMARK PHARMA  GSK PHARMA  CIPLA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views On News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 19, 2018 02:53 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ALEMBIC LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS